These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19892248)

  • 21. Novel potential therapies for septic shock.
    Azevedo LC; Park M; Schettino GP
    Shock; 2008 Oct; 30 Suppl 1():60-6. PubMed ID: 18704007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible?
    Opal SM; Patrozou E
    Crit Care Med; 2009 Jan; 37(1 Suppl):S10-5. PubMed ID: 19104207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombin replacement in patients with sepsis and septic shock.
    Giudici D; Baudo F; Palareti G; Ravizza A; Ridolfi L; D' Angelo A
    Haematologica; 1999 May; 84(5):452-60. PubMed ID: 10329925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid hormone supplementation in sepsis: an experimental study.
    Inan M; Koyuncu A; Aydin C; Turan M; Gokgoz S; Sen M
    Surg Today; 2003; 33(1):24-9. PubMed ID: 12560903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture.
    Halter JM; Pavone LA; Steinberg JM; Gatto LA; DiRocco J; Landas S; Nieman GF
    Shock; 2006 Dec; 26(6):587-91. PubMed ID: 17117134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Animal models of sepsis: setting the stage.
    Buras JA; Holzmann B; Sitkovsky M
    Nat Rev Drug Discov; 2005 Oct; 4(10):854-65. PubMed ID: 16224456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autonomic dysfunction in experimental sepsis induced by cecal ligation and puncture.
    Pancoto JA; Corrêa PB; Oliveira-Pelegrin GR; Rocha MJ
    Auton Neurosci; 2008 Feb; 138(1-2):57-63. PubMed ID: 18060845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and conduct of clinical trials: development of a clinical study based on animal data.
    Hinshaw LB
    Prog Clin Biol Res; 1988; 264():51-60. PubMed ID: 3289034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of tempol, a membrane-permeable radical scavenger, on mesenteric blood flow and organ injury in a murine cecal ligation and puncture model of septic shock.
    Yuksel BC; Serdar SE; Tuncel A; Uzum N; Ataoglu O; Atan A; Hengirmen S; Iskit AB; Guc MO
    Eur Surg Res; 2009; 43(2):219-27. PubMed ID: 19556798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of animal models for application to clinical trials in septic shock.
    Hinshaw LB
    Prog Clin Biol Res; 1989; 308():835-46. PubMed ID: 2675071
    [No Abstract]   [Full Text] [Related]  

  • 31. Experimental gram-negative pneumonia produces a hyperdynamic septic profile.
    Keenan RJ; Todd TR; Girotti MJ
    Circ Shock; 1987; 22(4):303-9. PubMed ID: 3652394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sepsis and septic shock--a review of laboratory models and a proposal.
    Wichterman KA; Baue AE; Chaudry IH
    J Surg Res; 1980 Aug; 29(2):189-201. PubMed ID: 6997619
    [No Abstract]   [Full Text] [Related]  

  • 33. Possible therapies of septic shock: based on animal studies and clinical trials.
    Wu CC
    Curr Pharm Des; 2006; 12(27):3535-41. PubMed ID: 17017946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of immunocompromised animals as models for human septic shock.
    Opal SM; Cross AS
    Shock; 2005 Dec; 24 Suppl 1():64-70. PubMed ID: 16374375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nicotinamide: a jack of all trades (but master of none?).
    Szabó C
    Intensive Care Med; 2003 Jun; 29(6):863-866. PubMed ID: 12712240
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluating myocardial depression in sepsis.
    Levy RJ; Deutschman CS
    Shock; 2004 Jul; 22(1):1-10. PubMed ID: 15201694
    [No Abstract]   [Full Text] [Related]  

  • 37. Why have new effective therapies for sepsis not been developed?
    Eidelman LA; Sprung CL
    Crit Care Med; 1994 Aug; 22(8):1330-4. PubMed ID: 7661904
    [No Abstract]   [Full Text] [Related]  

  • 38. Implementing refinements in preclinical sepsis modeling: walking a fine line between what ethics condones and the gaping investigative holes call for.
    Osuchowski M; Redl H; Radermacher P
    Shock; 2015 Apr; 43(4):422-3. PubMed ID: 25768374
    [No Abstract]   [Full Text] [Related]  

  • 39. Introducing Critical Appraisal to studies of animal models investigating novel therapies in sepsis.
    Piper RD; Cook DJ; Bone RC; Sibbald WJ
    Crit Care Med; 1996 Dec; 24(12):2059-70. PubMed ID: 8968277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical sepsis models.
    van der Poll T
    Surg Infect (Larchmt); 2012 Oct; 13(5):287-92. PubMed ID: 23046077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.